Vaping, Explained: What It Actually Does to Your Brain

He was 19. A B.Tech student in his second year. His mother had brought him in because she noticed the small metal device on his desk — the kind that looks like a USB drive — and asked what it was. He told her it was "just flavour." Nothing dangerous. Nothing like a cigarette.

He had been vaping for two years. When I asked him how many times he vaped in a day, he genuinely couldn't count. He estimated 200-300 puffs. His concentration in class had dropped. His sleep was broken. When he tried to stop for a day, he felt anxious and irritable within eight hours.

He was clinically dependent on nicotine. And like most young people I see for vaping, he didn't know it — because vaping doesn't feel or look like the addictions we've been warned about.

This is what vaping actually does. Not in scare-tactic language. In the plain clinical facts I wish more of my patients had heard earlier.

What vaping is

A vape — or e-cigarette — is a battery-powered device that heats a liquid until it turns into aerosol, which the user inhales. The liquid contains:

• Nicotine — the same addictive chemical as in cigarettes, but often at higher concentrations
• Propylene glycol and glycerin — the carriers that turn into vapour when heated
• Flavourings — thousands of possible flavour compounds, most of them not tested for inhalation safety
• Sometimes: other additives, including cannabis compounds in some devices sold illegally

Devices come in many forms — disposable "puff bars", refillable pod systems, larger box mods. The common design goal in the last decade has been to make nicotine easier and smoother to inhale in higher doses, more discreetly, and for longer stretches.

What nicotine actually does to your brain

This is the part that gets skipped in most vaping content, and it is the most important part.

Nicotine reaches the brain within 10-20 seconds of inhalation. It binds to receptors called nicotinic acetylcholine receptors, which are concentrated in the ventral tegmental area — one of the brain's core reward circuits. When these receptors are activated, the brain releases dopamine.

This is the same final common pathway that alcohol, cocaine, gambling, and most addictive behaviours operate through.

The brain quickly notices the sudden dopamine surge and begins to compensate. It reduces the sensitivity of the reward circuit. It adapts to expect nicotine at regular intervals. Within weeks of regular use, two things happen:

• The brain now requires nicotine to feel normal, not high. The dopamine you used to get from ordinary life — a good conversation, an interesting task, a satisfying meal — feels smaller than it did before.
• Missing a dose produces withdrawal symptoms: restlessness, anxiety, irritability, difficulty concentrating, low mood. These are not "mental weakness." These are a documented neurobiological response.

This is the mechanism of nicotine dependence. It is exactly the same mechanism whether the nicotine came from a cigarette, a bidi, gutka, khaini, or a vape.

Why vaping is a specific problem

If the biology is the same, why do I write specifically about vaping?

Higher nicotine concentrations. A single disposable vape can deliver the nicotine equivalent of 40-50 cigarettes. Users often don't realise how much they are inhaling, because a vape doesn't have the visible markers a cigarette has — no ash, no butt, no obvious end.

Constant, low-visibility use. A person can vape while working, in class, in the car, in bed. This is very different from stepping out for a cigarette break. It means the nicotine dose across a day is often higher, and the brain never gets a meaningful gap between doses.

A young brain is more vulnerable. The prefrontal cortex — the brain region responsible for decision-making, impulse control, and reward regulation — continues to mature until roughly age 25. Introducing nicotine to a still-developing brain has documented effects on attention, mood regulation, and future addiction risk. This is why most young vaping patients I see also report changes in focus, sleep, and anxiety that predated the vaping being noticed by anyone else.

The "flavour, not nicotine" myth. Many patients — particularly younger ones — believe that flavoured vapes without visible smoke are essentially harmless. This is not true. Even the lowest-nicotine liquids commercially sold contain enough nicotine to produce dependence with regular use, and the health effects of chronic inhalation of flavour compounds are still poorly understood.

Regulatory context in India. India banned the production, import, and sale of e-cigarettes under the Prohibition of Electronic Cigarettes Act, 2019. In practice, devices are still widely available through informal networks, online, and via smuggled imports. Because there is no regulation, there is no quality control — meaning users often do not know what is actually in the liquid they are inhaling.

The "safer than smoking" argument — what's actually true

You will read, repeatedly, that vaping is "safer than smoking." This claim has some truth in it, and a lot of important context that usually gets left out.

The claim comes from the fact that a large number of the harms from cigarette smoking come from combustion — the process of burning tobacco produces tar, carbon monoxide, and hundreds of carcinogens that are not present in the same amounts in vape aerosol. On a purely per-inhalation basis, most public health researchers agree that cigarette smoke is more directly damaging to lung tissue than vape aerosol.

Three things that usually don't get said in the same sentence:

"Safer than smoking" does not mean safe. Vaping produces its own set of documented health effects — including EVALI (e-cigarette or vaping product use-associated lung injury), which caused thousands of hospitalisations in the US in 2019-2020; cardiovascular effects, including increased blood pressure and heart rate; and effects on lung function that are still being studied.

The comparison is between two forms of harm, not one form of harm and safety. If someone is currently a smoker and switches completely to vaping, the harm-reduction argument may hold up. If someone starts vaping without ever having smoked — which is the pattern for most Indian teenagers and young adults I see — the "safer than smoking" argument is irrelevant, because the alternative was never smoking.

Vaping is highly effective at creating new nicotine users. In every country where vaping became widespread, adolescent nicotine dependence rates rose. In the US, between 2011 and 2019, e-cigarette use among high-school students went from around 1.5% to 27.5%. Even in India, where vapes are technically illegal, informal surveys and clinical experience suggest a similar upward trajectory in younger populations.

Vaping might reduce harm for existing smokers who fully switch. It has almost certainly increased harm for a generation who would otherwise never have used nicotine at all.

Signs that vaping is becoming a problem

Nicotine dependence develops quietly. Most people do not notice it until they try to stop and discover they can't. Some specific signs I look for in clinic:

• Vaping first thing in the morning, sometimes within minutes of waking
• Vaping in situations where you clearly can't (long flights, exam halls, meetings) — and feeling restless the whole time
• Difficulty concentrating on tasks you used to be able to focus on
• Sleep that is more fragmented than it used to be
• Anxiety that is worst first thing in the morning and settles after the first vape of the day
• Trying to cut down and finding yourself back at your usual level within days
• Losing track of how much you actually vape in a day
• Continuing to vape despite noticing a clear personal reason to stop

If several of these apply to you, or to someone you love, this is worth taking seriously — regardless of what the vape marketing has told you about "just flavour."

Why quitting is hard

Nicotine has one of the shortest craving-to-relief times of any addictive substance. From craving to dopamine release is under 20 seconds. The brain learns this cycle extremely quickly. Within weeks of regular use, the pattern is neurochemically established.

This is why quitting on willpower alone rarely works. What research consistently shows:

• The first 72 hours are the hardest. Craving intensity peaks in the first 24-72 hours and then progressively decreases. Most quit attempts that fail, fail in the first 3 days.
• After 3 days, the physical component of withdrawal is largely done. What remains is the behavioural pattern — the automatic reach for the device in specific situations. This part takes longer to unlearn.
• Individual craving waves last 90 seconds to 3 minutes. If you can ride out a single craving without vaping, the wave passes. The brain doesn't know you didn't vape — it moves on to the next thing.

If you are actively trying to quit, my 72-Hour Quit Toolkit is a structured, evidence-informed protocol designed specifically for that window. Free. No login. Nothing tracked.

What actually helps clinically

There are three legs to effective treatment for nicotine dependence:

Behavioural intervention. Cognitive-behavioural therapy for smoking cessation, motivational interviewing, and structured behaviour change protocols all have evidence bases. The specific technique matters less than having a structured approach, tracking, and a plan for triggers.

Pharmacological support. Options include:

• Nicotine Replacement Therapy (NRT) — patches, gums, lozenges. These deliver a controlled, tapering dose of nicotine without the delivery high, allowing the brain to gradually reset. Available in India.
• Bupropion — an antidepressant with independent anti-craving effects for nicotine. Prescription only.
• Varenicline — one of the most effective medications for nicotine dependence, though availability in India is limited.

Combination therapy — behavioural intervention plus pharmacological support — has consistently better outcomes than either approach alone.

Environmental change. Where and when a person vapes matters. Keeping the device on your desk, in your pocket, next to your bed makes quitting harder. Physically removing access, changing the environments where you typically vape, and identifying the two or three triggers where you vape most reliably — this is often where the real work happens.

When to see a psychiatrist

Most people can approach a first quit attempt on their own or with a general practitioner's guidance. Consider seeing a psychiatrist familiar with addiction if:

• You have made multiple serious attempts and relapsed
• You have a history of depression, anxiety, or another mental health condition
• Vaping is co-occurring with other substance use — alcohol, cannabis, other tobacco products
• You experience severe withdrawal symptoms
• You have ADHD or suspected ADHD (nicotine dependence is common with ADHD, and treatment approaches shift when both are present)

For anyone in Delhi NCR, I see nicotine dependence patients at Umang Mind and Brain Clinic. For those elsewhere in India, a psychiatrist with specific interest in addiction psychiatry is the right referral.

The takeaway

Vaping is not "just flavour." It is a nicotine delivery system optimised to be easy, low-visibility, and highly reinforcing to a still-developing brain.

The health effects are still being studied, but the dependence mechanism is already well understood — and clinically indistinguishable from any other form of nicotine addiction.

The good news: nicotine dependence is one of the more treatable addictions we deal with in psychiatry. Structured behavioural intervention plus, where appropriate, pharmacological support has consistently good outcomes. The first 72 hours are the hardest. After that, it gets progressively easier.

If you or someone you love is dealing with this — the full vaping resource page, including a self-assessment, treatment overview, and the 72-hour quit toolkit, is the next stop.

You don't have to do this alone.

References

1. Bhatnagar A, Whitsel LP, Ribisl KM, et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation. 2019;140(19):e937-e955.
2. Cullen KA, Gentzke AS, Sawdey MD, et al. E-cigarette use among youth in the United States, 2019. JAMA. 2019;322(21):2095-2103.
3. Werneck AO, Silva DR, Malta DC, Souza-Junior PRB, Azevedo LO, Barros MBA, Szwarcwald CL. Physical inactivity and elevated TV-viewing reported changes during the COVID-19 pandemic are associated with mental health: a survey with 43,995 Brazilian adults. Journal of Psychosomatic Research. 2021;140:110292.
4. Government of India. Prohibition of Electronic Cigarettes (Production, Manufacture, Import, Export, Transport, Sale, Distribution, Storage and Advertisement) Act, 2019.
5. Global Adult Tobacco Survey (GATS-2), India, 2016-17. Ministry of Health and Family Welfare, Government of India.
6. Benowitz NL. Nicotine addiction. New England Journal of Medicine. 2010;362(24):2295-2303.
7. World Health Organization. WHO report on the global tobacco epidemic, 2021: addressing new and emerging products. Geneva: WHO; 2021.
8. Hartmann-Boyce J, McRobbie H, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews. 2021;4:CD010216.
9. National Academies of Sciences, Engineering, and Medicine. Public Health Consequences of E-Cigarettes. Washington, DC: The National Academies Press; 2018.
10. Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin — final report. New England Journal of Medicine. 2020;382(10):903-916.

About the author

Dr. Sidharth Sood is a super-specialist in Addiction Psychiatry, trained at the All India Institute of Medical Sciences (AIIMS), New Delhi. He practices at Umang Mind and Brain Clinic and consults across Delhi NCR. His clinical work focuses on ADHD, addictions, and disorders of impulse, reward, and control.

Decoding impulse, addiction, and the brain.

For consulting, corporate wellness programs, media requests, and speaking engagements: connect on LinkedIn.

Follow: Instagram · LinkedIn

Last updated: July 2026. Content is educational and does not constitute personalized medical advice.